Skip to main content
ConductScienceScienceDex
NIH funding notice PAR-22-103

Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)

Closed on December 4, 2024.

Posted
January 21, 2022
Close date
December 4, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,433,582 in first-year total cost, median $716,791.

Most frequent study sections

  1. Special Emphasis Panel[ZAA1 DD (44)]2

Most frequent institutions

  1. ACEPRE, LLC1
  2. GENETOBE INC.1
Competing awards under PAR-22-103 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023A Precision Medicine for Alcohol-Associated Liver Disease1UT2AA031151-01BISGAIER, CHARLES LARRYLIU, WANQINGGENETOBE INC., MI$976,742ZAA1
2023Developing natural compound emodin as a therapy for alcoholic cardiomyopathy1UT1AA030690-01CARVER, WAYNE EFAN, DAPINGACEPRE, LLC, SC$456,840ZAA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
PAR-22-103: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional) | ScienceDex | ConductScience